Abstract

Tumor lymphangiogenesis is an important early event in tumorigenesis, one that promotes lymphatic metastasis. BRG1 (also known as SMARCA4) is a central component of the SWI/SNF chromatin-remodeling complex. In a previous work, we have reported that decreased BRG1 could promote colon cancer cell migration and invasion, and that the BRG1 expression level is negatively correlated with lymphatic metastasis. In the current study, we provide a comprehensive analysis of the role of BRG1 during lymphangiogenesis in colorectal cancer. Lymphatic vessels are more abundant in BRG1 low-expression tumors than in BRG1 high-expression tumors. We investigate the process by which BRG1 can promote VEGFC transcription and induce lymphangiogenesis in vivo and in vitro. We show that BRG1 controls lymphangiogenesis by binding to STAT3 and regulating STAT3 activation. We also prove the mechanisms through clinical samples. In summary, our demonstration of the important roles of the BRG1/STAT3/VEGFC in tumor-associated lymphangiogenesis might lead to the discovery of novel therapeutic targets in the treatment of cancers with BRG1 loss of function.

Highlights

  • Lymphatic metastasis is an important factor determining the outcome of colorectal cancer (CRC) [1, 2]

  • We have reported that decreased BRG1 could promote colon cancer cell migration and invasion, and that the BRG1 expression level is negatively correlated with lymphatic metastasis

  • We have reported that decreased BRG1 expression plays a critical role in CRC metastasis; we reported that the BRG1 loss function could promote colon cancer cell migration and invasion and www.impactjournals.com/oncotarget that the BRG1 expression level is negatively correlated with lymphatic metastasis [13]

Read more

Summary

Introduction

Lymphatic metastasis is an important factor determining the outcome of colorectal cancer (CRC) [1, 2]. Tumor lymphangiogenesis is an important early event in tumorigenesis, which can promote lymphatic metastasis [4,5,6]. Previous studies have reported that VEGFC/VEGFD play an important role in lymphangiogenesis [7, 8]. It has been indicated that VEGFC or VEGFD can bind vascular endothelial growth factor receptor-3 (VEGFR-3), as well as promote tumor lymphangiogenesis and prevent the spread of lymphatic tumor to regional lymph nodes [4, 9]. Targeting VEGFC/VEGFR-3 pathway for lymph node metastasis and reducing the incidence of distant organ metastases have been given a therapeutic approach [9]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.